OSR2 and cancer: A pan-cancer analysis with 10,967 tumor samples in 32 TCGA cohorts revealed that a low frequency of ALDH1A2 (1.4%), OSR2 (5%), GRIA4 (3%), GATA4 (4%), and IRX4 (5%) was genetically altered.